113507-06-5 Usage
Description
Moxidectin is a macrocyclic lactone endectocide and a derivative of nemadectin. It reduces fecal nematode egg counts by 98.4 and 99.8% in naturally infected calves when administered subcutaneously at doses of 0.2 and 0.3 mg/kg, respectively. Moxidectin (0.2 and 0.3 mg/kg) reduces the worm burden of O. ostertagi and T. axei in the abomasum, and Cooperia species and N. helvetianus in the small intestine, of naturally infected calves. It potentiates GABA-gated currents in Xenopus oocytes expressing rat α1β2γ2 subunit-containing GABAA receptors with an EC50 value of 11.8 nM. Formulations containing moxidectin have been used in the treatment of onchocerciasis, as well as in the prevention and treatment of parasitic infections in veterinary medicine.
Uses
Different sources of media describe the Uses of 113507-06-5 differently. You can refer to the following data:
1. anthelmintic, antiparasitic
2. Moxidectin is a macrocyclic lactone and semisynthetic derivative of nemadectin. Moxidectin is a parasiticide used for the prevention and control of heartworm and intestinal worms. Moxidectin is is fou
nd in veterinary medicine used to treat animals such as dogs, cats, horses, cattle and sheep.
3. Moxidectin is a semi-synthetic milbemycin derived from nemadectin by selective oxidation followed by methyloximation. Moxidectin was patented in 1991 as an anthelmintic for internal parasite control. The presence of the methyloxime affords moxidectin a greater hydrophobicity and longer biological half-life compared to nemadectin. Moxidectin binds selectively to parasite glutamate-gated chloride ion channels and disrupts neurotransmission leading to paralysis and death of the parasite.
Veterinary Drugs and Treatments
In dogs and cats, moxidectin with lufenuron is indicated as a once
a month topical preventative for the prevention of heartworm, flea
adulticide, ear mites (cats) and treatment for hookworms, roundworms,
and whipworms (dogs). It has also been successfully used as
a treatment for generalized demodicosis.
In cattle, moxidectin is indicated for the treatment and control
of the following internal [adult and fourth stage larvae (L4)]
and external parasites: Gastrointestinal roundworms: Ostertagia
ostertagi (adult and L4, including inhibited larvae), Haemonchus
placei (adult), Trichostrongylus axei (adult and L4), Trichostrongylus
colubriformis (adult), Cooperia oncophora (adult), Cooperia punctata
(adult), Bunostomum phlebotomum (adult), Oesophagostomum
radiatum (adult), Nematodirus helvetianus (adult); Lungworm:
Dictyocaulus viviparus (adult and L4); Cattle Grubs: Hypoderma
bovis, Hypoderma lineatum Mites: Chorioptes bovis, Psoroptes
ovis (Psoroptes communis var. bovis); Lice: Linognathus vituli,
Haematopinus eurysternus, Solenopotes capillatus, Damalinia bovis;
Horn flies: Haematobia irritans. To control infections and to protect
from reinfection from Ostertagia ostertagi for 28 days after treatment
and from Dictyocaulus viviparus for 42 days after treatment.
In sheep, oral moxidectin is indicated for the control of
Haemonchus contortus (adult and L4), Teladosrsagia circumcincta
& trifurcata (adult and L4), Trichostrongylus colubriformis, axei, &
vitrinius (adult & L4), Cooperia curticei & oncophora (adult and L4),
Oesophagostomum columbianum & venolosum (adult & L4), and
Nematodirus battus, filicollis, & spathiger (adult & L4).
In horses and ponies, moxidectin is indicated for the treatment
and control of the following stages of gastrointestinal parasites:
Large strongyles: Strongylus vulgaris (adults and L4L5 arterial
stages); Strongylus edentatus (adults and tissue stages);
Triodontophorus brevicauda (adults); Triodontophorus serratus
(adults); Small strongyles (adults and larvae): Cyathostomum spp.
(adults); Cylicocyclus spp. (adults); Cylicostephanus spp. (adults);
Gyalocephalus capitatus (adults); undifferentiated lumenal larvae;
Encysted cyathostomes: late L3 and L4 mucosal cyathostome larvae;
Ascarids: Parascaris equorum (adults and L4 larval stages); Pin
worms: Oxyuris equi (adults and L4 larval stages); Hair worms:
Trichostrongylus axei (adults); Large-mouth stomach worms:
Habronema muscae (adults); Horse stomach bots: Gasterophilus intestinalis
(2nd and 3rd instars). When combined with praziquantel,
additional coverage against Anoplocephala spp. occurs.
Check Digit Verification of cas no
The CAS Registry Mumber 113507-06-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,3,5,0 and 7 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 113507-06:
(8*1)+(7*1)+(6*3)+(5*5)+(4*0)+(3*7)+(2*0)+(1*6)=85
85 % 10 = 5
So 113507-06-5 is a valid CAS Registry Number.
InChI:InChI=1/C37H53NO8/c1-21(2)14-25(6)33-26(7)31(38-42-8)19-36(46-33)18-29-17-28(45-36)13-12-23(4)15-22(3)10-9-11-27-20-43-34-32(39)24(5)16-30(35(40)44-29)37(27,34)41/h9-12,14,16,21-22,26,28-30,32-34,39,41H,13,15,17-20H2,1-8H3/b10-9+,23-12+,25-14+,27-11+,38-31-/t22-,26-,28+,29-,30-,32+,33+,34+,36-,37+/m0/s1
113507-06-5Relevant articles and documents
Method for preparing moxidectin
-
Paragraph 0046; 0053-0054; 0073-0078, (2020/09/08)
The invention discloses a method for preparing moxidectin. The method sequentially comprises the following steps: with nemadectin is used as a raw material performing substitution, oxidization and de-protection reactions on allyl chlorocarbonate; The invention discloses a novel synthesis route, wherein used raw materials have characteristics of wide and sufficient source; the method has advantagesof proper cost, simple process, mild reaction conditions of each step, conventional operation, and production cost reducing.
A method of preparing mosictin
-
Paragraph 0101-0104, (2017/03/23)
The invention relates to a method for preparation of moxidectin. The method includes subjecting Nemadectin to protective reaction, oxidation reaction, oximation reaction and deprotection reaction in order, thus obtaining moxidectin. Specifically, the protective agent employed in the protective reaction is tert-butyl dimethylchlorosilane, and after the oximation reaction, the solid form crude product obtained by the oximation reaction is subjected to crystallization, and then the deprotection reaction is carried out on the obtained crystal. The method provided by the invention increases the product content, further reduces the difficulty for follow-up utilization of macroporous resin for purification, and improves the column loading amount, reduces the number of column chromatography, maintains or even improves the purity of the final product, and lowers the production cost.
